Fda provides roadmap for accelerated approval pathway through submission of additional cnm-au8® biomarker data in als

Salt lake city, dec. 10, 2024 (globe newswire) -- clene inc. (nasdaq: clnn) (along with its subsidiaries, “clene”) and its wholly owned subsidiary clene nanomedicine inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (als) and multiple sclerosis (ms), today announced that it recently received written guidance from the division of neurology 1 (dn1), of the u.s. food and drug administration (fda) regarding a potential accelerated approval pathway for cnm-au8 ® in als.
CNM Ratings Summary
CNM Quant Ranking